Generics International (US), Inc.
11
James L. Garrity Jr.
08/16/2022
04/26/2023
Yes
v
| MEGANY, MEGA, JtAdm, CLMAGT |
Assigned to: Judge James L. Garrity Jr. Chapter 11 Voluntary Asset |
|
Debtor Generics International (US), Inc.
6 Ram Ridge Road Chestnut Ridge, NY 10977 ROCKLAND-NY Tax ID / EIN: 26-1166489 dba Par Pharmaceutical dba Qualitest Merger Sub, Inc. dba Generics International (US), LLC |
represented by |
Paul D. Leake
Skadden, Arps, Slate, Meagher & Flom LLP One Manhattan West New York, NY 10001 212-735-3000 Fax : 212-735-2000 Email: paul.leake@skadden.com Kyle J. Ortiz
Togut, Segal & Segal LLP One Penn Plaza Suite 3335 New York, NY 10119 212-594-5000 Fax : 212-967-4258 Email: kortiz@teamtogut.com |
U.S. Trustee United States Trustee
Office of the United States Trustee U.S. Federal Office Building 201 Varick Street, Room 1006 New York, NY 10014 (212) 510-0500 |
| |
Claims and Noticing Agent Kroll Restructuring Administration LLC Claims Agent
(Formerly Prime Clerk LLC) 55 East 52nd Street 17th Floor www.kroll.com New York, NY 10055 (212) 257-5450 |
| Date Filed | # | Docket Text |
|---|---|---|
| 11/10/2022 | 12 | Schedules filed: Schedule A/B - Non-Individual, Schedule D - Non-Individual, Schedule E/F - Non-Individual, Schedule G - Non-Individual, Schedule H - Non-Individual /Global Notes, Summary and Schedules of Assets and Liabilities for Generics International (US), Inc. Filed by Kyle J. Ortiz on behalf of Generics International (US), Inc.. (Ortiz, Kyle) (Entered: 11/10/2022) |
| 10/27/2022 | 11 | Motion to Extend Deadline to File Schedules or Provide Required Information /(Hearing Date: 11/10/2022 at 11:00 AM, Objections Due: 11/3/2022 at 4:00 PM) Notice of Hearing and Motion of Debtors for Entry of an Order Further Extending Time to File Schedules of Assets and Liabilities and Statements of Financial Affairs (Attachment: Exhibit A: Proposed Order) filed by Kyle J. Ortiz on behalf of Generics International (US), Inc. with hearing to be held on 11/10/2022 at 11:00 AM at Videoconference (ZoomGov) (JLG) Objections due by 11/3/2022,. (Ortiz, Kyle) (Entered: 10/27/2022) |
| 10/25/2022 | 10 | Order signed on 10/24/2022 Granting Motion To Extend Deadline to File Schedules or Provide Required Information. Deadline: 10/31/2022 (Related Doc # 9) (Rodriguez, Willie) (Entered: 10/25/2022) |
| 09/27/2022 | 9 | Motion to Extend Deadline to File Schedules or Provide Required Information /(Hearing Date: October 13, 2022 at 11:00 a.m., Objection Deadline: October 6, 2022 at 4:00 p.m.) Notice of Hearing and Motion of Debtors for Entry of an Order Extending Time to File Schedules of Assets and Liabilities and Statements of Financial Affairs (Attachments: Exhibit A: Proposed Order) filed by Kyle J. Ortiz on behalf of Generics International (US), Inc. with hearing to be held on 10/13/2022 at 11:00 AM at Videoconference (ZoomGov) (JLG) Objections due by 10/6/2022,. (Ortiz, Kyle) (Entered: 09/27/2022) |
| 09/12/2022 | Party Kroll Restructuring Administration LLC Claims Agent added to the case.. (Rodriguez, Willie). (Entered: 09/12/2022) | |
| 09/09/2022 | 8 | Order signed on 9/6/2022 Granting Motion Appointing Kroll Restructuring Administration LLC as Claims and Noticing Agent. (Related Doc # 6) (Rodriguez, Willie) (Entered: 09/09/2022) |
| 08/25/2022 | 7 | Order signed on 8/23/2022 Granting Motion To Extend Deadline to File Schedules or Provide Required Information. Deadline: 9/29/2022 (Related Doc # 3) (Rodriguez, Willie) (Entered: 08/25/2022) |
| 08/18/2022 | 6 | Motion to Appoint Kroll Restructuring Administration LLC as Claims and Noticing Agent /Application of the Debtors for an Order (I) Appointing Kroll Restructuring Administration LLC as Claims and Noticing Agent Nunc Pro Tunc to the Petition Date; and (II) Granting Related Relief filed by Paul D. Leake on behalf of Generics International (US), Inc.. (Leake, Paul) (Entered: 08/18/2022) |
| 08/18/2022 | Case Jointly Administered with 22-22549 (Rodriguez, Willie). (Entered: 08/18/2022) | |
| 08/17/2022 | 5 | Order signed on 8/17/2022 in accordance with Rule 1015(b) of the Federal Rules of Bankruptcy Procedure directing the procedural consolidation and joint administration of the chapter 11 cases of Endo International plc and its affiliates that have concurrently commenced chapter 11 cases. The docket in the chapter 11 case of Endo International plc (3755), Case No. 22-22549 (JLG), should be consulted for all matters affecting the chapter 11 cases of : 70 Maple Avenue, LLC (1491); Actient Pharmaceuticals LLC (7232); Actient Therapeutics LLC (2019); Anchen Incorporated (8760); Anchen Pharmaceuticals, Inc. (9179); Astora Womens Health Ireland Limited (5829); Astora Womens Health, LLC (0427); Auxilium International Holdings, LLC (9643); Auxilium Pharmaceuticals, LLC (6883); Auxilium US Holdings, LLC (8967); Bermuda Acquisition Management Limited (N/A); BioSpecifics Technologies LLC (4851); Branded Operations Holdings, Inc. (6945); DAVA International, LLC (9945); DAVA Pharmaceuticals, LLC (7354); Endo Aesthetics LLC (0218); Endo Bermuda Finance Limited (4093); Endo Designated Activity Company (7135); Endo Eurofin Unlimited Company (2009); Endo Finance IV Unlimited Company (2779); Endo Finance LLC (6481); Endo Finance Operations LLC (6355); Endo Finco Inc. (5794); Endo Generics Holdings, Inc. (4834); Endo Global Aesthetics Limited (2898); Endo Global Biologics Limited (2735); Endo Global Development Limited (4785); Endo Global Finance LLC (7754); Endo Global Ventures (4244); Endo Health Solutions Inc. (2871); Endo Innovation Valera, LLC (3622); Endo Ireland Finance II Limited (0535); Endo LLC (6640); Endo Luxembourg Finance Company I S. r.l. (3863); Endo Luxembourg Holding Company S..r.l. (7168); Endo Luxembourg International Financing S..r.l. (2905); Endo Management Limited (4866); Endo Par Innovation Company, LLC (2435); Endo Pharmaceuticals Finance LLC (5768); Endo Pharmaceuticals Inc. (5829); Endo Pharmaceuticals Solutions Inc. (7911); Endo Pharmaceuticals Valera Inc. (9931); Endo Procurement Operations Limited (7840); Endo TopFin Limited (8086); Endo U.S. Inc. (0786); Endo US Holdings Luxembourg I S..r.l. (7910); Endo Ventures Aesthetics Limited (9967); Endo Ventures Bermuda Limited (0688); Endo Ventures Cyprus Limited (1544); Endo Ventures Limited (6029); Generics Bidco I, LLC (6905); Generics International (US) 2, Inc. (5075); Generics International (US), Inc. (6489); Generics International Ventures Enterprises LLC (4685); Hawk Acquisition Ireland Limited (4776); Innoteq, Inc. (3381); JHP Acquisition, LLC (7861); JHP Group Holdings, LLC (7688); Kali Laboratories 2, Inc. (6751); Kali Laboratories, LLC (4898); Luxembourg Endo Specialty Pharmaceuticals Holding I S. r.l. (0601); Moores Mill Properties L.L.C. (9523); Paladin Labs Canadian Holding Inc. (N/A); Paladin Labs Inc. (1410); Par Laboratories Europe, Ltd. (9597); Par Pharmaceutical 2, Inc. (4895); Par Pharmaceutical Companies, Inc. (8301); Par Pharmaceutical Holdings, Inc. (3135); Par Pharmaceutical, Inc. (8342); Par Sterile Products, LLC (0105); Par, LLC (1286); Quartz Specialty Pharmaceuticals, LLC (5368); Slate Pharmaceuticals, LLC (6201); Timm Medical Holdings, LLC (8744); and Vintage Pharmaceuticals, LLC (7882). (Related Doc # 2) (Rodriguez, Willie) (Entered: 08/17/2022) |